James A. Retsema - Concepedia

Author

James A. Retsema

Also Known As

J A Retsema, J Retsema, J. A. RETSEMA, J. A. Retsema, J. Retsema, JAMES A. RETSEMA, James A Retsema, PhD, James A. Retsema

Publications

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Institute of Medicinal Plant Development University of Iowa

About

James A. Retsema is an author at Pfizer (United States) specializing in medicine, drug resistance, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.9K
2	Health Sciences	11	11	1.3K
3	Natural Sciences	5	5	255
4	Biochemistry	5	5	316
5	Allergy	1	1	48

James A. Retsema

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms James A. Retsema, Agnès Girard, W Schelkly, Antimicrobial Agents and Chemotherapy Antimicrobial ChemotherapyDrug ResistanceMacrolide Antibiotic AzithromycinImproved PotencyNew 15-Membered-ring Macrolide	1987	458
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization A. R. English, James A. Retsema, Arthur E. Girard, Antimicrobial Agents and Chemotherapy	1978	393
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b> Joanna Clancy, J.W. Petitpas, Fadia B. Dib-Hajj, Molecular Microbiology Novel Macrolide‐resistance DeterminantBacteriologyMolecular BiologyFunctional AnalysisAntibiotic Resistance	1996	360
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution Agnès Girard, D Girard, A. R. English, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntimicrobial ChemotherapyNew MacrolideAnimal Infection Models	1987	321
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides. G. Michael Bright, A. Nagel, Jon Bordner, The Journal of Antibiotics	1988	237
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection Jay Bergeron, Mark Ammirati, Dennis E. Danley, Antimicrobial Agents and Chemotherapy Bioorganic ChemistryE. Coli StrainGlycobiologyMolecular BiologyRibosomal Protection	1996	154
Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection James A. Retsema, A. R. English, Agnès Girard, Clinical Infectious Diseases Klebsiella PneumoniaeEscherichia ColiAntimicrobial ChemotherapyAntibiotic ResistanceVitro Spectrum	1986	106
Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450 David E. Amacher, Shelli Schomaker, James A. Retsema Antimicrobial Agents and Chemotherapy Azithromycin-dosed RatsPharmacotherapyAntimicrobial ChemotherapyDrug ResistancePharmacological Study	1991	87
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides James A. Retsema, A. R. English, Agnès Girard Antimicrobial Agents and Chemotherapy Weak Antibacterial ActivityAntimicrobial SusceptibilityHealth SciencesAntibioticsPenicillin G	1980	82
Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo James A. Retsema, Agnès Girard, D Girard, Journal of Antimicrobial Chemotherapy Antimicrobial SusceptibilityHealth SciencesAntibioticsPneumoniae PopulationLung Infection Model	1990	74

Page 1